Novel Drug Trial To Treat Advanced Prostate Cancer Enrolling Patients At,, UCSF/Mount Zion Cancer Center

Advanced prostate cancer patients who have become resistant to standard hormone treatment therapy may be eligible to participate in a UCSF/Mount Zion Cancer Center clinical trial of a drug that researchers hope will inhibit the growth of blood vessels that nourish tumor cells.

The drug, developed by Genentech Inc., is a protein known as an antibody that inhibits a growth factor called VEGF, or vascular endothelial cell growth factor.

Many cells produce VEGF to help stimulate the growth and migration of blood vessels into the cellular environment in a beneficial way, as for supplying nutrients during wound healing. But many types of cancer cells also produce VEGF, and they produce higher than normal levels.

The UCSF/Mount Zion trial will attempt to ascertain whether the antibody to VEGF, called rhuMAb VEGF, will successfully block the development of blood vessels by prostate tumor cells. In laboratory studies, the antibody did inhibit the growth of human prostate cancer cells grown in animals.

"Considerable laboratory evidence suggests this drug works," said Eric Small, MD, UCSF associate clinical professor of medicine and urology and co-director of the Urologic Oncology Program at UCSF/Mount Zion Cancer Center. "We hope that anti-VEGF antibody will disrupt blood vessels and help slow or stop the growth of prostate cancer."

The anti-VEGF antibody is not the same drug as the compounds angiostatin and endostatin developed in Boston and the subject of recent news stories, although it appears to work by a similar mechanism. Anti-VEGF, like the other drugs, is intended to block the growth of blood vessels in and around tumor cells, thereby stopping the growth of the tumors themselves.

The new UCSF/Mount Zion study will be a phase II clinical trial, the stage of new drug testing designed to determine a drug's effectiveness.

To qualify for the anti-VEGF antibody trial at UCSF/Mount

Contact: Jennifer O'Brien
(415) 476-2557
University of California - San Francisco

Page: 1 2

Related biology news :

1. Novel IBD therapeutic approaches reported from Washington Univ., Barcelona, LSU at APS meeting
2. Novel therapeutic bortezomib moves to phase II trial in lung cancer patients
3. Novel approaches to current cellular therapies continue progress toward disease prevention
4. Novel therapies show promise against myeloid leukemia
5. Novel sensors help clear the air
6. Fox Chase Cancer Center study: Novel DNA-repair gene mutation can cause resistance to cancer drugs
7. Novel proteins designed that block inflammation regulator associated with rheumatoid arthritis
8. Novel therapeutic target identified in fight against Rheumatoid Arthritis
9. Novel bacterium detoxifies chlorinated pollutants
10. Novel flu vaccine shows promise in mice
11. Novel gene therapy on the horizon, says Brenner Childrens Hospital pediatrician

Post Your Comments:

(Date:6/13/2020)... ... June 11, 2020 , ... ... significant expansion of its forensic genealogy team. Bode’s Forensic Genealogy Service (FGS) ... forensic genealogy and DNA analysis methods. The team has added experienced genealogists, each ...
(Date:6/11/2020)... , ... June 09, 2020 , ... Superior Controls, ... industrial automation and IT solutions for the life sciences industry, is pleased to announce ... Development working out of the company’s Seabrook, New Hampshire office. In his new ...
(Date:6/5/2020)... Calif. (PRWEB) , ... June 04, 2020 , ... “Although ... the health and well-being of our attendees, staff, and the public. We remain ... unique and safe ways to collaborate virtually,” said Julie Sutcliffe, President of WMIS. ...
Breaking Biology News(10 mins):
(Date:6/11/2020)... (PRWEB) , ... June 09, 2020 , ... ... the release of the NEON Micro-Tracer Solution, a highly accurate, contact ... COVID-19 virus in the workplace. Contact tracing, a core disease control measure, is ...
(Date:6/2/2020)... ... 01, 2020 , ... As part of its ongoing mission ... world, enterprise security solutions provider bitsIO donated time to help two companies improve ... self-quarantines and shelter-in-place orders, companies are increasingly concerned about the security of their ...
(Date:5/28/2020)... ... May 28, 2020 , ... Genedata, the leading provider of ... Screener ® 17.0, the latest version of its enterprise software for the automated ... Genedata will host a webinar on June 10, 2020, detailing and demonstrating the ...
(Date:5/21/2020)... ... , ... Threats to intellectual property, political pressure to lower ... wisdom that says the coronavirus pandemic will generally benefit biopharmaceutical companies, a new ... commercially weaker, dealing with delays in new product launches and with fewer resources ...
Breaking Biology Technology:
Cached News: